ArticleBMC women's health2026
Exploratory evaluation of a CEUS-derived substitution for solid-component measurement in the ADNEX model.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundAlthough the Assessment of Different Neoplasias in the adnexa (ADNEX) model has been widely validated, there remains challenges in differentiating true solid components from benign mimics. We aimed to evaluate the feasibility and value of substituting conventional ultrasound-derived solid component size with CEUS-derived measurements in the ADNEX model for adnexal lesions discrimination.
methodsThis multicenter prospective study recruited consecutive patients with suspected adnexal lesions with solid components detected at ultrasound between January 2022 and June 2024. All patients underwent preoperative CEUS examination. Pathological results serve as the reference standard. Each adnexal lesion was evaluated using ADNEX, a CEUS-based modified ADNEX score (CEUS-derived substitution for solid-component measurement without updating model coefficients) and Ovarian-Adnexal Reporting and Data System (O-RADS) Ultrasound (US) score.
resultsA total of 204 patients (median age, 47.0 years [IQR: 33.0-56.0 years]) with 204 lesions were included. The area under the receiver operating characteristic curve (AUROC) for CEUS-based modified ADNEX was 0.906 (95% CI: 0.867-0.944), which was superior to that of ADNEX (AUROC:0.865; 95% CI, 0.814-0.916; P = 0.019) and O-RADS US (AUROC: 0.783; 95% CI, 0.726 -0.840; P < 0.001) in classifying adnexal lesions with solid components. CEUS-based modified ADNEX demonstrated greater specificity (0.664) compared to ADNEX (0.283; P < 0.001) and O-RADS US (0.221; P < 0.001).
conclusionsCEUS-derived modification for solid-component measurement in the ADNEX model showed potential improvements in the diagnostic specificity and clinical benefit compared with the original ADNEX framework in the classification of adnexal lesions with solid components.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.